Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Issue 1 - Feb13

Risk of hyperkalaemia – trimethoprim in combination with spironolactone; Change in Dovobet® Portfolio; Omega-3 fatty acids (Omacor®) in patients with type 2 diabetes with cardiovascular disease; Eyes on Evidence; An alternative to Orlistat®; PPIs: risks of long-term use; Dressings – guidance for obtaining Non-Formulary dressings in exceptional circumstances; Repeat dispensing – reminder about pink forms; Midazolam buccal solutions – brand prescribing